These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 34445916)

  • 1. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
    Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
    Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
    Wong R; Fishman J; Wilson K; Yeh M; Al-Adhami M; Zion A; Yee CW; Huynh L; Duh MS
    Adv Ther; 2023 Apr; 40(4):1571-1589. PubMed ID: 36750531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
    Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
    N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
    Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R
    Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
    Heo YA
    Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors.
    Panse J; Daguindau N; Okuyama S; Peffault de Latour R; Schafhausen P; Straetmans N; Al-Adhami M; Persson E; Wong RSM
    PLoS One; 2024; 19(7):e0306407. PubMed ID: 39079163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
    Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
    Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
    Lee JW; Sicre de Fontbrune F; Wong Lee Lee L; Pessoa V; Gualandro S; Füreder W; Ptushkin V; Rottinghaus ST; Volles L; Shafner L; Aguzzi R; Pradhan R; Schrezenmeier H; Hill A
    Blood; 2019 Feb; 133(6):530-539. PubMed ID: 30510080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bresnahan R; Houten R; Greenhalgh J; Nevitt S; Mahon J; Beale S; Boland A; Bhattacharyya D; Dundar Y; McEntee J; Gandhi S; Fleeman N; Chaplin M
    Pharmacoecon Open; 2023 Jul; 7(4):525-536. PubMed ID: 37195551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
    de Latour RP; Szer J; Weitz IC; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro CM; Nishimori H; Ajayi T; Al-Adhami M; Deschatelets P; Francois C; Grossi F; Risitano AM; Hillmen P
    Lancet Haematol; 2022 Sep; 9(9):e648-e659. PubMed ID: 36055332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
    Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
    Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients.
    Ishiyama K; Nakao S; Usuki K; Yonemura Y; Ikezoe T; Uchiyama M; Mori Y; Fukuda T; Okada M; Fujiwara SI; Noji H; Rottinghaus S; Aguzzi R; Yokosawa J; Nishimura JI; Kanakura Y; Okamoto S
    Int J Hematol; 2020 Oct; 112(4):466-476. PubMed ID: 32869125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting.
    Hakimi Z; Wilson K; McAughey E; Pochopien M; Wojciechowski P; Toumi M; Knight C; Sarda SP; Patel N; Wiseman C; de Castro NP; Nazir J; Kelly RJ
    J Comp Eff Res; 2022 Sep; 11(13):969-985. PubMed ID: 35796199
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
    Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
    Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
    Di Matteo S; Freilone R; Bruno GM; Notaro R; Moumene S; Martone N; Teruzzi C; Ciccarone A; Colombo GL
    Clinicoecon Outcomes Res; 2024; 16():225-232. PubMed ID: 38623087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
    Wong RSM
    Ther Adv Hematol; 2022; 13():20406207221114673. PubMed ID: 35923770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
    de Castro C; Grossi F; Weitz IC; Maciejewski J; Sharma V; Roman E; Brodsky RA; Tan L; Di Casoli C; El Mehdi D; Deschatelets P; Francois C
    Am J Hematol; 2020 Nov; 95(11):1334-1343. PubMed ID: 33464651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria].
    Ishiyama K; Usuki K; Ikezoe T; Gotoh A; Myren KJ; Tomazos I; Shimono A; Ninomiya H; Sakurai M; Nakao S; Nishimura JI
    Rinsho Ketsueki; 2023; 64(1):9-17. PubMed ID: 36775313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
    Wong RSM; Pullon HWH; Amine I; Bogdanovic A; Deschatelets P; Francois CG; Ignatova K; Issaragrisil S; Niparuck P; Numbenjapon T; Roman E; Sathar J; Xu R; Al-Adhami M; Tan L; Tse E; Grossi FV
    Ann Hematol; 2022 Sep; 101(9):1971-1986. PubMed ID: 35869170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
    Brodsky RA; Peffault de Latour R; Rottinghaus ST; Röth A; Risitano AM; Weitz IC; Hillmen P; Maciejewski JP; Szer J; Lee JW; Kulasekararaj AG; Volles L; Damokosh AI; Ortiz S; Shafner L; Liu P; Hill A; Schrezenmeier H
    Haematologica; 2021 Jan; 106(1):230-237. PubMed ID: 31949012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.